<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03854227</url>
  </required_header>
  <id_info>
    <org_study_id>C3851001</org_study_id>
    <nct_id>NCT03854227</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors</brief_title>
  <official_title>A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06939999 (PRMT5 INHIBITOR) IN PARTICIPANTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, HEAD AND NECK SQUAMOUS CELL CARCINOMA, ESOPHAGEAL CANCER, ENDOMETRIAL CANCER, CERVICAL CANCER AND BLADDER CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open label, multi center, dose escalation and expansion, safety,&#xD;
      tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients&#xD;
      with advanced or metastatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2019</start_date>
  <completion_date type="Anticipated">February 11, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 12, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose Escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities (DLTs)</measure>
    <time_frame>Baseline through day 28</time_frame>
    <description>DLTs will be evaluated during the first cycle. The number of DLTs will be used to determine the maximum tolerated dose (MTD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment emergent adverse events (AEs)</measure>
    <time_frame>Baseline through up to 2 years or until disease progression</time_frame>
    <description>Adverse events as characterized by type, frequency, severity, timing, seriousness and relationship to study therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with laboratory abnormalities</measure>
    <time_frame>Baseline through up to 2 years or until disease progression</time_frame>
    <description>Laboratory abnormalities as characterized by type, frequency, severity, and timing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Baseline through up to 2 years or until disease progression</time_frame>
    <description>Best Overall Response by RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Single dose PK will be calculated including Maximum Observed Plasma Concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Time to reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Single dose PK will be calculated including Time to reach Maximum Observed Plasma Concentration (Tmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Area Under the Curve from time 0 to the last sampling time point within the dose interval (AUClast)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Single dose PK will be calculated including Area Under the Curve from time 0 to the last sampling time point within the dose interval (AUClast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Terminal elimination half life (t1/2)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Single dose PK will be calculated including, as data permit, terminal elimination half life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: AUC from time 0 extrapolated to infinity (AUCinf)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Single dose PK will be calculated including, as data permit, Area Under the Curve from time 0 extrapolated to infinity (AUCinf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Apparent oral plasma clearance (CL/F)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Single dose PK will be calculated including, as data permit, apparent oral plasma clearance (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Apparent volume of distribution (Vz/F)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Single dose PK will be calculated including, as data permit, apparent volume of distribution (Vz/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Maximum Observed Steady State Plasma Concentration (Css,max)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Multiple dose PK will be calculated including Maximum Observed Steady State Plasma Concentration (Css,max).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Time to reach Maximum Observed Steady State Plasma Concentration (Tss,max)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Multiple dose PK will be calculated including Time to reach Maximum Observed Steady State Plasma Concentration (Tss,max).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Area Under the Curve within one dose interval (AUCss,t)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Multiple dose PK will be calculated including Area Under the Curve within one dose interval (AUCss,t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Steady state apparent oral plasma clearance (CL/F)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8. 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Multiple dose PK will be calculated including, as data permit, steady state apparent oral plasma clearance (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Steady state apparent volume of distribution (Vss/F)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Multiple dose PK will be calculated including, as data permit, steady state apparent volume of distribution (Vss/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Accumulation ratio (Rac)</measure>
    <time_frame>Cycle 1 Days 1 and 15, predose, 0.5, 1, 2, 4, 6 and 12 hours post dose; predose on Cycle 1 Days 2, 8, 16 and 22 and predose on Day 1 of every Cycle (each cycle is 28 days) thereafter until month 24</time_frame>
    <description>Multiple dose PK will be calculated including, as data permit, accumulation ratio (Rac)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Baseline through up to 2 years or until disease progression</time_frame>
    <description>DOR as assessed using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Baseline through up to 2 years or until disease progression</time_frame>
    <description>PFS as assessed using RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>Baseline through up to 2 years or until disease progression</time_frame>
    <description>TTP as assessed using RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline through up to 2 years</time_frame>
    <description>Proportion of participants alive at 6 months, 1 year and 2 years.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PF-06939999 orally at escalating doses in 28 day cycles on a continuous basis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non small cell lung cancer monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Urothelial carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Head and neck squamous cell carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non small cell lung cancer PF-06939999 plus docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PF-06939999 on a continuous basis in combination with docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non small cell lung cancer dose finding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PF-06939999 on a continuous basis at escalating doses in combination with docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06939999 dose escalation</intervention_name>
    <description>PF-06939999 orally at escalating doses on a continuous basis</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <other_name>PRMT5 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06939999 monotherapy</intervention_name>
    <description>PF-06939999 at the recommended Phase 2 dose orally on a continuous basis</description>
    <arm_group_label>Head and neck squamous cell carcinoma</arm_group_label>
    <arm_group_label>Non small cell lung cancer monotherapy</arm_group_label>
    <arm_group_label>Urothelial carcinoma</arm_group_label>
    <other_name>PRMT5 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06939999 in combination with docetaxel</intervention_name>
    <description>PF-06939999 orally on a continuous basis in combination with docetaxel</description>
    <arm_group_label>Non small cell lung cancer PF-06939999 plus docetaxel</arm_group_label>
    <arm_group_label>Non small cell lung cancer dose finding</arm_group_label>
    <other_name>PRMT5 inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed locally advanced or metastatic NSCLC,&#xD;
             urothelial carcinoma or HNSCC&#xD;
&#xD;
          -  Progressed after at least 1 line of treatment and no more than 3 lines of treatment&#xD;
&#xD;
          -  At least one measurable lesion as defined by RECIST version 1.1&#xD;
&#xD;
          -  ECOG Performance Status 0 or 1&#xD;
&#xD;
          -  Adequate Bone Marrow Function&#xD;
&#xD;
          -  Adequate Renal Function&#xD;
&#xD;
          -  Adequate Liver Function&#xD;
&#xD;
          -  Resolved acute effects of any prior therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known active uncontrolled or symptomatic CNS metastases.&#xD;
&#xD;
          -  Major surgery, radiation therapy, systemic anti-cancer therapy or investigational&#xD;
             drug(s) within 4 weeks prior to study entry.&#xD;
&#xD;
          -  Active, uncontrolled infection, including COVID-19&#xD;
&#xD;
          -  Known or suspected hypersensitivity to PF-06939999&#xD;
&#xD;
          -  Inability to consume or absorb study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scottsdale Healthcare Hospitals d/b/a HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia G. Piper Cancer Pharmacy</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keck Hospital of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LAC + USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AdventHealth Celebration Infusion Center</name>
      <address>
        <city>Celebration</city>
        <state>Florida</state>
        <zip>34747</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AdventHealth Medical Group Oncology Research at Celebration</name>
      <address>
        <city>Celebration</city>
        <state>Florida</state>
        <zip>34747</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Cancer Institute at Memorial Regional Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AdventHealth Hematology and Oncology</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando - Investigational Drug Services</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando Infusion Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Cancer Institute at Memorial Hospital West</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute, Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute - Downtown</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute Downtown</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norton Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland Greenebaum Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Brighton</name>
      <address>
        <city>Brighton</city>
        <state>Michigan</state>
        <zip>48114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Cancer Institute-Downriver</name>
      <address>
        <city>Brownstown</city>
        <state>Michigan</state>
        <zip>48183</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center-Fairlane</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center - Columbus</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System / Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Diagnostic Associates</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Overlook Medical Center</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prisma-Health Institute for Translational Oncology Research</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry-Joyce Cancer Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology IDS Pharmacy</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3851001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

